TITLE:
Does Rifaximin Improve EEG and VEP in Egyptian Cirrhotic Patients with Minimal Hepatic Encephalopathy?
AUTHORS:
Amr Mohamed Abdelfattah, Al-Amir Bassiouny Mohamed, Gharib Fawi, Badr Ragab, Hassan M. Elnady, Mohamed Malak
KEYWORDS:
MHE, EEG, VEP, Rifaximin
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.8 No.10,
October
24,
2018
ABSTRACT: Background: Minimal hepatic Encephalopathy (MHE) is defined as HE without symptoms on clinical/neurological examination, but with deficits in some cognitive areas that can only be measured by neuropsychometric testing. However, numerous studies have shown that, although the neurological symptoms are slight, affected patients are markedly impaired in their quality of life and ability to work. Various treatment modalities that have been shown to reverse MHE include lactulose/lactitol, probiotics/synbiotics, L-carnitine but rifaximin has shown a general trend toward better efficacy and better tolerability in patients with overt hepatic encephalopathy (OHE). Objective: Our objective is to assess the diagnostic role of minimental state examination (MMSE), electroencephalography (EEG) and visual evoked potential (VEP) in detection of MHE and to evaluate the efficacy of rifaximin in improving EEG and VEP in patients with MHE. Patients and Methods: Sixty cirrhotic patients were enrolled in the study depending on clinical evidence of stigmata of chronic liver disease, laboratory investigations including liver function tests, ultrasonographic features of liver cirrhosis and with no evidence of overt hepatic encephalopathy. Diagnois of MHE was made depending on minimental state examination (MMSE) and neurophysiological tools including EEG and VEP. A control group of sixty healthy volunteers with age and sex matched were included. The patient group received Rifaximin 550 mg twice daily for 8 weeks then follow up EEG and VEP studies were done. Results: MHE was detected in 36.7%, 48.3%, 51.7% of our series based on MMSE, EEG and VEP respectively. Child Pouph A, B, C was found in 51.7%, 35%, 13.3% respectively. Rifaximin was well tolerated. At the end of treatment, EEG and VEP studies were done which showed signficant changes between pre and post treatment results (P value = 0.03, 0.001, Conclusion: MMSE as well as EEG and VEP were reasonable diagnostic tools for early detection of MHE particularly in countries with low level of education. Rifaximin significantly improves both EEG and VEP in cirrhotic patients with MHE.